182 related articles for article (PubMed ID: 8824370)
21. 4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
Buchdunger E; Mett H; Trinks U; Regenass U; Müller M; Meyer T; Beilstein P; Wirz B; Schneider P; Traxler P
Clin Cancer Res; 1995 Aug; 1(8):813-21. PubMed ID: 9816050
[TBL] [Abstract][Full Text] [Related]
22. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
23. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
24. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases.
Shimizu M; Adachi S; Masuda M; Kozawa O; Moriwaki H
Mol Nutr Food Res; 2011 Jun; 55(6):832-43. PubMed ID: 21538846
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
[TBL] [Abstract][Full Text] [Related]
26. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.
Fry DW; Kraker AJ; Connors RC; Elliott WL; Nelson JM; Showalter HD; Leopold WR
Anticancer Drug Des; 1994 Aug; 9(4):331-51. PubMed ID: 7916900
[TBL] [Abstract][Full Text] [Related]
27. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention.
Neergheen VS; Bahorun T; Taylor EW; Jen LS; Aruoma OI
Toxicology; 2010 Dec; 278(2):229-41. PubMed ID: 19850100
[TBL] [Abstract][Full Text] [Related]
28. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.
Blair JA; Rauh D; Kung C; Yun CH; Fan QW; Rode H; Zhang C; Eck MJ; Weiss WA; Shokat KM
Nat Chem Biol; 2007 Apr; 3(4):229-38. PubMed ID: 17334377
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer.
Wallerand H; Robert G; Bernhard JC; Ravaud A; Patard JJ
Arch Esp Urol; 2010 Nov; 63(9):773-87. PubMed ID: 21098902
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase inhibitors.
Workman P; Brunton VG; Robins DJ
Semin Cancer Biol; 1992 Dec; 3(6):369-81. PubMed ID: 1286158
[TBL] [Abstract][Full Text] [Related]
31. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program.
Posner I; Engel M; Gazit A; Levitzki A
Mol Pharmacol; 1994 Apr; 45(4):673-83. PubMed ID: 8183246
[TBL] [Abstract][Full Text] [Related]
32. Oncogene signal transduction inhibitors from medicinal plants.
Chang CJ; Ashendel CL; Geahlen RL; McLaughlin JL; Waters DJ
In Vivo; 1996; 10(2):185-90. PubMed ID: 8744799
[TBL] [Abstract][Full Text] [Related]
33. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Carmi C; Mor M; Petronini PG; Alfieri RR
Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
[TBL] [Abstract][Full Text] [Related]
34. Role of growth factors and their receptors in the control of normal cell proliferation and cancer.
Wahl MI; Carpenter G
Clin Physiol Biochem; 1987; 5(3-4):130-9. PubMed ID: 3040317
[TBL] [Abstract][Full Text] [Related]
35. Label-free electrochemical measurement of protein tyrosine kinase activity and inhibition based on electro-catalyzed tyrosine signaling.
Yang Y; Guo LH; Qu N; Wei MY; Zhao LX; Wan B
Biosens Bioelectron; 2011 Oct; 28(1):284-90. PubMed ID: 21820892
[TBL] [Abstract][Full Text] [Related]
36. The potential use of tyrosine kinase inhibitors in severe asthma.
Guntur VP; Reinero CR
Curr Opin Allergy Clin Immunol; 2012 Feb; 12(1):68-75. PubMed ID: 22157153
[TBL] [Abstract][Full Text] [Related]
37. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases.
Bridges AJ
Curr Med Chem; 1999 Sep; 6(9):825-43. PubMed ID: 10495354
[TBL] [Abstract][Full Text] [Related]
38. Folic acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines.
Jaszewski R; Khan A; Sarkar FH; Kucuk O; Tobi M; Zagnoon A; Dhar R; Kinzie J; Majumdar AP
Am J Physiol; 1999 Dec; 277(6):C1142-8. PubMed ID: 10600765
[TBL] [Abstract][Full Text] [Related]
39. Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro.
Gray ME; Lee S; McDowell AL; Erskine M; Loh QTM; Grice O; Argyle DJ; Bergkvist GT
Vet Comp Oncol; 2017 Sep; 15(3):890-909. PubMed ID: 27229930
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.
Denny WA; Rewcastle GW; Bridges AJ; Fry DW; Kraker AJ
Clin Exp Pharmacol Physiol; 1996 May; 23(5):424-7. PubMed ID: 8713682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
